Roche SA
122.7 FTEThe score of Roche shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +11 % Equity +6 % Total assets +3 % Headcount (avg FTE) -16 %
Accounts of the company itself (not consolidated). Consolidated group accounts are also filed: they are in the full file.
The full file covers 10 financial years; a free account shows 2. →Roche's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 10 Jun 2024
- Year ended 31 Dec 2022filed on 09 May 2023
- Year ended 31 Dec 2021filed on 29 Apr 2022
Roche's financial analysis
- Solvency39.1%sector median: 41.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Roche
Roche's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.088.151
- VAT number
- BE0403088151
- Peppol
- Registered · 0208:0403088151 · as of 29 Oct 2026
- Legal form
- SA
- Incorporated
- 12 Feb 1924
- Registered office
- 1070 Anderlecht
- Size
- Medium · 122.7 FTE
- Latest accounts
- 2025 · filed on 09 Jun 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Roche (SA) has been based in Anderlecht since 1924, active in: manufacture of medicaments. For 2025, it reports revenue of €448.8m, a net profit of €8.74m and equity of €64.5m. With 122.7 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 39.1%, below the median of its sector (41.4%).
Companies similar to Roche
Companies in the same business, of comparable size and area, outside its group.
- SERB Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €159.3m
- PHOENIX Pharma Belgium Manufacture of pharmaceutical preparations Woluwe-Saint-Lambert · balance sheet €235.4m
- Novartis Pharma Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €168.8m
- Sanofi Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €218.9m
- JNTL Consumer Health (Belgium) Manufacture of basic pharmaceutical products Antwerp · balance sheet €156.0m
- Alcon Laboratories Belgium Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €107.2m
- AstraZeneca Wholesale of pharmaceutical and medical goods Dilbeek · balance sheet €105.4m
- Pfizer Manufacture of pharmaceutical preparations Ixelles · balance sheet €377.4m
Frequently asked questions about Roche
What is the revenue of Roche?
According to the 2025 annual accounts filed with the NBB, the revenue of Roche amounts to 448,791,077 €.
What is the VAT number of Roche?
In Belgium, the VAT number is the company number prefixed with BE: BE0403088151 for Roche, if the company is VAT-registered. Its company number (CBE) is 0403.088.151.
Where is the registered office of Roche?
According to the CBE register, the registered office of Roche is in 1070 Anderlecht.
What is the equity of Roche?
At the close of the 2025 financial year, the equity of Roche amounts to 64,460,286 €, a solvency of 39.1% of total assets.
How many people work at Roche?
122.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Roche?
The register lists 5 active mandates at Roche. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Roche
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →